Last reviewed · How we verify
Oxfendazole single dose
Oxfendazole single dose is a Small molecule drug developed by Universidad Peruana Cayetano Heredia. It is currently in Phase 2 development. Also known as: Intervention 1.
Oxfendazole is a small molecule that inhibits tubulin, a protein involved in cell division. It has been studied as a treatment for various parasitic infections, including trichuriasis, tenia solium infection, fascioliasis, and brain cysticercosis, among others.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oxfendazole single dose |
|---|---|
| Also known as | Intervention 1 |
| Sponsor | Universidad Peruana Cayetano Heredia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults (PHASE2)
- One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis (PHASE2)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults (PHASE2)
- PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets (PHASE1)
- Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole (PHASE1)
- Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults (PHASE2)
- Single Ascending Dose Safety Study of Oxfendazole (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxfendazole single dose CI brief — competitive landscape report
- Oxfendazole single dose updates RSS · CI watch RSS
- Universidad Peruana Cayetano Heredia portfolio CI
Frequently asked questions about Oxfendazole single dose
What is Oxfendazole single dose?
Who makes Oxfendazole single dose?
Is Oxfendazole single dose also known as anything else?
What development phase is Oxfendazole single dose in?
Related
- Manufacturer: Universidad Peruana Cayetano Heredia — full pipeline
- Also known as: Intervention 1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing